Source: PharmaTimes
Area: News
According to PharmaTimes, Novartis has announced that it will file for EU approval of ranibizumab for myopic choroidal neovascularisation (CNV) by the end of 2012, based on positive results from the REPAIR study. This one-year study (n=65) found that ranibizumab 0.5mg intravitreal injection, given when required (individualised based on outcomes) resulted in a mean visual acuity improvement of 12 letters after six months (mean of three injections). Just under one-third of patients (29%) only required one injection. No further details of the study are provided in (Read more...)
Uncategorized